PRIMARY STUDY
Cannabinoid hyperemesis syndrome in North America: evaluation of health burden and treatment prevalence
Key Findings: This analysis of the experience and prevalence of patients with cannabis hyperemesis syndrome (CHS) found that most patients also suffer from cannabis use disorder (CUD), and that emergency department visits increased significantly after cannabis legalization and again during the COVID-19 pandemic.
Type of Study: Meta-analysis
Study Sample Size: 157
Study Result: Negative
Research Location(s): Canada, United States
Year of Pub: 2022
Cannabinoids Studied: Cannabinoid (unspecified)
Phytocannabinoid Source: Unspecified
Citation: Andrews CN, et al. Cannabinoid hyperemesis syndrome in North America: evaluation of health burden and treatment prevalence. Aliment Pharmacol Ther. 2022; 56:1532-1542. doi: 10.1111/apt.17265
Authors: Andrews CN, Rehak R, Woo M, Walker I, Ma C, Forbes N, Rittenbach K, Hathaway J, Wilsack L, Liu A, Nasser Y, Sharkey KA
